Cold agglutinin disease
Clinical trials for Cold agglutinin disease explained in plain language.
Never miss a new study
Get alerted when new Cold agglutinin disease trials appear
Sign up with your email to follow new studies for Cold agglutinin disease, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug calm the immune System's attack on blood cells?
Disease control CompletedThis study is testing an experimental drug called povetacicept in adults with autoimmune cytopenias — conditions where the immune system mistakenly destroys blood cells, leading to low platelet counts (immune thrombocytopenia) or anemia (autoimmune hemolytic anemia and cold agglu…
Matched conditions: COLD AGGLUTININ DISEASE
Phase 1/2 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug shows promise for rare blood disorder
Disease control CompletedThis study tested a drug called pegcetacoplan in 24 adults with cold agglutinin disease, a rare condition where the immune system destroys red blood cells. Participants received either the drug or a placebo twice a week for 24 weeks. The goal was to see if the drug could raise he…
Matched conditions: COLD AGGLUTININ DISEASE
Phase 3 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug BIVV020 tested for rare blood disorder
Disease control CompletedThis early-stage trial tested a single dose of the drug BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system mistakenly attacks red blood cells. The main goal was to see if the drug is safe and tolerable. Researchers also looked at how it af…
Matched conditions: COLD AGGLUTININ DISEASE
Phase 1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Japanese CAD patients get continued access to experimental drug sutimlimab
Disease control CompletedThis study gave sutimlimab to 7 adults in Japan with cold agglutinin disease (CAD) who had already completed earlier trials and still needed treatment. The goal was to monitor safety and side effects over time until the drug became commercially available. It is a small, open-labe…
Matched conditions: COLD AGGLUTININ DISEASE
Phase 3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 26, 2026 17:23 UTC